Targeted Oncology Staff

NeOnc's intranasal NEO100 met its primary end point in a phase 2a trial of recurrent IDH1-mutant glioma, reaching 48.9% 6-month PFS vs a 20% benchmark.

Zipalertinib plus platinum-based chemotherapy significantly improved progression-free survival at a planned interim analysis of the phase 3 REZILIENT3 trial.

During a live event, Eric K. Singhi, MD, and participants discussed how CNS activity and cumulative toxicity, not guideline listing alone, are shaping frontline treatment selection in ROS1-positive advanced NSCLC.

The FDA has granted breakthrough device designation to Freenome's SimpleScreen Lung, an investigational blood-based test for high-risk lung cancer screening.

Experts weigh response speed, survival and quality of life to choose first-line IO-TKI or dual immunotherapy for metastatic clear cell RCC.

This analysis builds on results from the phase 3 KEYNOTE-689 trial of perioperative pembrolizumab in head and neck squamous cell carcinoma.

The complete response letter did not cite any clinical issues regarding the NDA for 177Lu-edotreotide for GEP-NETs.

During a live event, Sikander Ailawadhi, MD, and participants discussed how the route of CD38-antibody delivery, including a newly approved on-body injector, is shaping frontline regimen selection for transplant-ineligible multiple myeloma.

The FDA's Molecular and Clinical Genetics Panel will meet Sept. 23, 2026, to evaluate GRAIL's premarket approval application for the Galleri MCED test.

A multimodal deep learning model trained in the NSABP B-42 trial and validated in TAILORx predicted late distant recurrence risk in HR-positive breast cancer.

Neoadjuvant inetetamab plus pyrotinib and chemotherapy achieved a 60.2% total pathologic complete response rate in the phase 2 neoPICD trial.

Explore how REMS removal streamlines CAR T-cell access in second-line DLBCL, plus smart bridging options and who qualifies when relapse strikes fast.

Large Ontario cohort study finds lifetime breast and ovarian cancer risk varies sharply by BRCA1/BRCA2 test result, including in those with inconclusive or negative findings.

Experts weigh TiNivo-2 and CONTACT-03, urging caution on PD-1 rechallenge in RCC and guiding tivozanib vs cabozantinib choices.

Jazz moves to drop Zepzelca’s second-line SCLC use after LAGOON misses survival, while first-line maintenance combo remains approved.

During a live event, Millie Das, MD, and participants discussed why the case for adding a CTLA-4 inhibitor in PD-L1–low metastatic NSCLC does not hold uniformly once histology is taken into account.

Neo-CheckRay shows iSBRT plus durvalumab boosts pCR in high-risk ER+/HER2− breast cancer, especially PD-L1–negative “cold” tumors, with higher immune toxicity.

FDA tentatively OKs cabozantinib capsules for renal cell carcinoma, hepatocellular carcinoma, and epNETs, with dose-conversion guidance, error warning, and improved absorption.

During a live event, Midhun Malla, MD, MS, and participants discussed toxicity considerations with third-line therapy selection for KRAS-mutant mCRC.

NCCN now prefers gedatolisib plus fulvestrant, with or without palbociclib, for PIK3CA wild-type HR+/HER2– metastatic breast cancer after endocrine therapy.

The July 2026 oncology roundup spotlights rapid cancer drug approvals, new dosing options, a melanoma virus therapy vote, and key rejections shaping treatment trends.

Digital app-based therapy helps breast cancer survivors reduce anxiety over 12 months; however, depression gains lagged.

WinPro trial shows adding micronized progesterone to pre-surgery letrozole fails to boost Ki67 suppression in ER+/PR+ breast cancer, but may ease hot flushes.

FDA fast-tracks ISM6331 for hard-to-treat pleural mesothelioma, spotlighting Hippo pathway targeting and early phase 1 results presented at ESMO 2026.

Real-world data show Enhertu drives strong responses in HER2-mutant NSCLC, including brain metastases, while highlighting ILD risks and dosing insights.

SimpleScreen CRC has demonstrated a sensitivity of 81.1% for CRC detection.

Responses seen in more than half of treatment-naive patients, including those with low PD-L1 expression, in the TROPION-Lung02 study.

Study aims to lift pathological complete response above the roughly 5% seen with chemotherapy alone in resectable disease.

FIT-001 updates show darlifarnib plus cabozantinib drives 33% to 50% responses and 13‑month PFS in pretreated patients with cabozantinib-naive ccRCC.

Experts break down second-line CAR T for relapsed DLBCL—who qualifies, what to expect, and why logistics still block access.